Scarica l'app Stockscreener
9.27
4.63%
0.41
Dopo l'orario di chiusura:
9.04
-0.23
-2.48%
Precedente Chiudi:
$8.86
Aprire:
$8.76
Volume 24 ore:
76,878
Relative Volume:
1.18
Capitalizzazione di mercato:
$88.86M
Reddito:
$789.00K
Utile/perdita netta:
$5.70M
Rapporto P/E:
11.44
EPS:
0.81
Flusso di cassa netto:
$865.00K
1 W Prestazione:
-0.64%
1M Prestazione:
+3.46%
6M Prestazione:
-55.94%
1 anno Prestazione:
-31.64%
Intervallo 1D:
$8.76
$9.335
Intervallo di 1 settimana:
$8.46
$9.5511
Portata 52W:
$6.53
$29.98
Seres Therapeutics Inc Stock (MCRB) Company Profile
Nome
Seres Therapeutics Inc
Settore
Industria
Telefono
617 945 9626
Indirizzo
200 SIDNEY STREET, CAMBRIDGE, MA
Compare MCRB vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MCRB
Seres Therapeutics Inc
|
9.27 | 88.86M | 789.00K | 5.70M | 865.00K | 0.81 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Seres Therapeutics Inc Stock (MCRB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-08 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2024-10-24 | Downgrade | JP Morgan | Neutral → Underweight |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-21 | Iniziato | JP Morgan | Neutral |
| 2021-07-23 | Downgrade | Goldman | Neutral → Sell |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-03-05 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2020-09-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-08-11 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-04-30 | Iniziato | Jefferies | Hold |
| 2018-10-22 | Iniziato | Chardan Capital Markets | Buy |
| 2017-10-13 | Iniziato | Oppenheimer | Outperform |
| 2017-08-04 | Reiterato | H.C. Wainwright | Buy |
| 2017-02-01 | Reiterato | FBR & Co. | Outperform |
| 2016-08-12 | Reiterato | FBR Capital | Outperform |
| 2016-08-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2016-08-01 | Reiterato | H.C. Wainwright | Buy |
| 2016-07-29 | Ripresa | H.C. Wainwright | Buy |
| 2016-03-30 | Iniziato | FBR Capital | Outperform |
| 2016-03-03 | Iniziato | Guggenheim | Buy |
| 2016-01-25 | Iniziato | H.C. Wainwright | Buy |
| 2015-10-22 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2015-07-22 | Iniziato | Canaccord Genuity | Buy |
| 2015-07-21 | Iniziato | Goldman | Neutral |
| 2015-07-21 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Seres Therapeutics Inc Borsa (MCRB) Ultime notizie
MCRB SEC FilingsSeres Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Market Fear: Can Seres Therapeutics Inc weather a recessionDip Buying & Free High Return Stock Watch Alerts - baoquankhu1.vn
MCRB stock declines as Seres Therapeutics pauses SER-155 phase 2 study and shrinks headcount by 30% - MSN
Market Rankings: Is Seres Therapeutics Inc in a bullish channelTrade Volume Summary & Safe Capital Growth Stock Tips - baoquankhu1.vn
Layoff Tracker: Takeda Restructuring Will Affect Workforce, Could Include Layoffs - BioSpace
Seres Therapeutics (NASDAQ:MCRB) Stock Price Crosses Below 50 Day Moving AverageHere's Why - MarketBeat
Seres Therapeutics cuts 25% of workforce to extend cash runway into Q2 2026 - MSN
Seres Therapeutics (MCRB) price target increased by 31.25% to 21.42 - msn.com
If You Invested $1,000 in Seres Therapeutics Inc (MCRB) - Stock Titan
Seres Therapeutics Sets 2026 Annual Shareholder Meeting Date - The Globe and Mail
MCRB (NASDAQ: MCRB) files Form 144 to resell 8,553 restricted shares - Stock Titan
Kelly Brady Net Worth (2026) - GuruFocus
Seres Therapeutics schedules 2026 annual meeting for June 9 By Investing.com - Investing.com India
Seres Therapeutics schedules 2026 annual meeting for June 9 - Investing.com
Seres Therapeutics sets 2026 annual meeting for June 9; shareholder proposal deadline Mar 26 - TradingView
Seres Therapeutics (MCRB) schedules 2026 meeting, sets proposal deadline - Stock Titan
Seres Therapeutics, Inc. (NASDAQ:MCRB) Short Interest Down 15.4% in February - MarketBeat
MCRB: Canaccord Genuity Maintains Buy Rating with $22 Target | M - GuruFocus
Seres Therapeutics (NASDAQ:MCRB) Receives Buy Rating from Canaccord Genuity Group - MarketBeat
Exit Recap: Is Seres Therapeutics Inc impacted by rising rates2026 Macro Impact & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Seres Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
Seres Therapeutics (NASDAQ:MCRB) Releases Earnings Results, Beats Expectations By $0.50 EPS - MarketBeat
Seres Therapeutics 2025 10-K: $0.8M Revenue, net income $5.70M - TradingView
Seres Therapeutics: Q4 Earnings Snapshot - marketscreener.com
Seres Therapeutics Reports 2025 Results, Highlights Refocused Pipeline - TipRanks
Seres (MCRB) Focuses on Advancing Biotherapeutics Portfolio - GuruFocus
Seres Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates - Bitget
Seres Therapeutics: Fourth Quarter Earnings Overview - Bitget
Seres Therapeutics (NASDAQ: MCRB) details 2025 profit, cash runway and SER-155 progress - Stock Titan
Seres Therapeutics (MCRB) awards 56,250 stock options to officer - Stock Titan
Seres Therapeutics (MCRB) officer Brady Kelly reports stock holdings - Stock Titan
Seres Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Seres Therapeutics Inc expected to post a loss of $2.11 a shareEarnings Preview - TradingView
Is Seres Therapeutics Incs ROE strong enough2025 Trading Recap & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Rally Mode: Should I invest in Seres Therapeutics Inc before earningsGold Moves & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Activity Recap: Should I invest in Seres Therapeutics Inc before earningsWeekly Stock Report & AI Forecasted Stock Moves - baoquankhu1.vn
Aug Action: Does Seres Therapeutics Inc have declining or rising EPSMarket Sentiment Report & Daily Entry Point Alerts - baoquankhu1.vn
Seres Therapeutics (MCRB) director Richard Kender awarded 150,000 stock options - Stock Titan
Seres Therapeutics (MCRB) grants 75,000-share stock option to officer Henn - Stock Titan
The Escalator: Seres Therapeutics, Bavarian Nordic, Moderna and more - Medical Marketing and Media
Seres Therapeutics (MCRB) Projected to Post Earnings on Thursday - MarketBeat
Human Microbiome Therapeutics Market to Reach US$ 5.86 Billion - openPR.com
MCRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Seres Therapeutics Inc Azioni (MCRB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):